[Genomics-創] Results of the Company's Price Stabilization Operations for the First Five Business Days of Listing on the Innovation Board

1. Date of occurrence of the event: 2026/05/15 2. Company name: Genomics BioSci & Tech Co., Ltd. 3. Relationship to the Company (please enter "head office" or "subsidiary"): Head office 4. Reciprocal shareholding ratios: Not applicable 5. Cause of occurrence: In accordance with the "Guidelines for Underwriters Handling Initial Public Offering (IPO) Cases by the Taiwan Securities Association," the Company announces the results of the stable price operations for the first five business days of its listing. 6. Countermeasures: None 7. Any other matters that need to be specified (if the subject of the event or resolution is a public company or above, this material message also meets the criteria for matters having a significant impact on shareholders' equity or securities prices under Article 7, Paragraph 9 of the Securities and Exchange Act Enforcement Rules): (1) Lead underwriter: Taichung Commercial Bank Securities Co., Ltd. (2) Name and code of securities: Genomics-創 (Stock Code: 4195) (3) Actual number of over-allotment shares: 130,000 shares (4) Underwriting price: NT$22.06 per share (5) Proceeds from over-allotment: NT$2,867,800 (6) Execution period of stabilization operations: 2026/05/11 ~ 2026/05/15 (7) Cumulative number of shares purchased by the lead underwriter's "Stable Price Operation Account": 130,000 shares